Sleep Medicine News

Pear Therapeutics reported new data that reinforce the effectiveness of Somryst, its prescription digital therapeutic for chronic insomnia in adults.

The U.S. Senate recently passed legislation that would make daylight saving time permanent starting in 2023.

After a long winter, the switch to daylight saving time on March 13 may seem like a welcome sign of spring.

WEST PALM BEACH, Florida — Physical activity levels and sleep correlated with psychological outcomes in MS, according to data presented at the ACTRIMS Forum.

The reported prevalence of melatonin use significantly increased among adults in the United States during a recent 20-year period, survey data show.

Healio’s most-viewed neurology stories in January highlight several FDA developments, a Medicare proposal to limit Aduhelm coverage and a study on the role of Epstein-Barr virus infection in MS.

Many adults with a traumatic brain injury had a persistent form of insomnia for up to 12 months, according to a prospective cohort study published in JAMA Network Open.

Quviviq 25 mg and 50 mg enhanced sleep among patients with insomnia disorder, according to results of two randomized, double-blind, placebo-controlled, phase 3 trials published in The Lancet Neurology.

The FDA granted approval to Quviviq to treat adults with insomnia.

Excessive daytime sleepiness, nonrestorative sleep and sleep behaviors all play a significant role in sleep health, according to results of a network analysis of sleep variables published in Sleep Epidemiology.